NCT02068365View on ClinicalTrials.gov

An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Chronic Hepaititis B
Interventions
DRUG

Pegyinterferon-alfa-2a

Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks

Trial Locations (1)

Unknown

Prince of Wales Hospital, Shatin

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT02068365 - An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy | Biotech Hunter | Biotech Hunter